Secondary endoscopic end point results (Lanza and erosion scores) at week 6
| End point | AZD3582 | Naproxen | Placebo | AZD3582 v naproxen estimated ratio (95% CI) |
|---|---|---|---|---|
| Lanza score | ||||
| Incidence (%) of significant gastroduodenal damage (Lanza scores 3 and 4) | 32.2 | 43.7 | 7.0 | 0.7 (0.6 to 0.9) |
| Within-subject change (from baseline to week 6) | ||||
|---|---|---|---|---|
| AZD3582 | Naproxen | Placebo | AZD3582 v naproxen estimated pairwise differences (95% CI) | |
| *10 erosions were considered to represent one ulcer. | ||||
| CI, confidence interval. | ||||
| Erosion score | ||||
| Number of erosions and ulcers* in: | ||||
| Stomach and duodenum | 3.1 | 5.5 | −0.1 | 2.5 (1.1 to 3.8) |
| Stomach only | 2.2 | 4.1 | −0.1 | 2.0 (0.9 to 3.0) |
| Duodenum only | 0.9 | 1.4 | 0 | 0.5 (−0.2 to 1.2) |
| Oesophagus only | 0.2 | 0.01 | −0.05 | −0.07 (−0.32 to 0.18) |
| Number of erosions in: | ||||
| Stomach and duodenum | 1.6 | 3.4 | −0.1 | 1.8 (0.8 to 2.7) |
| Stomach only | 1.4 | 2.9 | −0.1 | 1.5 (0.6 to 2.4) |
| Duodenum only | 0.2 | 0.5 | 0 | 0.3 (0.04 to 0.52) |
| Oesophagus only | 0.06 | 0.09 | −0.04 | 0.02 (−0.07 to 0.11) |